Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study
ABSTRACT Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records t...
Gespeichert in:
| Veröffentlicht in: | Influenza and other respiratory viruses 2024-04, Vol.18 (4), p.e13292-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 4 |
| container_start_page | e13292 |
| container_title | Influenza and other respiratory viruses |
| container_volume | 18 |
| creator | Monge, Susana Humphreys, James Nicolay, Nathalie Braeye, Toon Van Evercooren, Izaak Holm Hansen, Christian Emborg, Hanne‐Dorthe Sacco, Chiara Mateo‐Urdiales, Alberto Castilla, Jesús Martínez‐Baz, Iván Gier, Brechje Hahné, Susan Meijerink, Hinta Kristoffersen, Anja Bråthen Machado, Ausenda Soares, Patricia Nardone, Anthony Bacci, Sabrina Kissling, Esther Nunes, Baltazar |
| description | ABSTRACT
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA. |
| doi_str_mv | 10.1111/irv.13292 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11040092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3046019831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4042-3c1e166d713dffc9533f9bb2829e24933c1aa6251ea7f10e6113b4b044481c9e3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhiMEohdY8ALIEhsqMTO-JZOwQXMJdKTSQS0dsbMc56S4TexiJ6lmxyPwFrwXT4KnU0YFCW_Okc7n_1z-KHpB8JCEN9KuHxJGM_oo2ifjGA9oEmePdznHe9GB91cYx0ka86fRHkuTmPM03o9-5lUFqtU9GPAe2Qp9mU6HZBijj9bYXtZgWjRbrhbzX99_kAytpFI6oGjeOW0ukUSfwGlbPvw5t4020ihA2qD8YpTnEzSznWmdBv8GLVVrC3CotejU9tBscoope4smaJVPF-ehU358hk6hvbXuGp23Xbl-Fj2pZO3h-X08jC7e559nx4OT5YfFbHIyUBxzOmCKAEmSckxYWVUqixmrsqKgKc2A8oyFupQJjQnIcUUwJISwgheYh2sQlQE7jN5tdW-6ooFShfWdrMWN0410a2GlFn9XjP4qLm0vCMEc44wGhdf3Cs5-68C3otFeQV1LA7bzgmGexISleIO--ge9sp0zYb87CpMsZSRQR1tKOeu9g2o3DcFi478I_os7_wP78uH4O_KP4QEYbYFbXcP6_0picbbaSv4Gmbu3zg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3046019831</pqid></control><display><type>article</type><title>Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Monge, Susana ; Humphreys, James ; Nicolay, Nathalie ; Braeye, Toon ; Van Evercooren, Izaak ; Holm Hansen, Christian ; Emborg, Hanne‐Dorthe ; Sacco, Chiara ; Mateo‐Urdiales, Alberto ; Castilla, Jesús ; Martínez‐Baz, Iván ; Gier, Brechje ; Hahné, Susan ; Meijerink, Hinta ; Kristoffersen, Anja Bråthen ; Machado, Ausenda ; Soares, Patricia ; Nardone, Anthony ; Bacci, Sabrina ; Kissling, Esther ; Nunes, Baltazar</creator><creatorcontrib>Monge, Susana ; Humphreys, James ; Nicolay, Nathalie ; Braeye, Toon ; Van Evercooren, Izaak ; Holm Hansen, Christian ; Emborg, Hanne‐Dorthe ; Sacco, Chiara ; Mateo‐Urdiales, Alberto ; Castilla, Jesús ; Martínez‐Baz, Iván ; Gier, Brechje ; Hahné, Susan ; Meijerink, Hinta ; Kristoffersen, Anja Bråthen ; Machado, Ausenda ; Soares, Patricia ; Nardone, Anthony ; Bacci, Sabrina ; Kissling, Esther ; Nunes, Baltazar ; VEBIS‐EHR Working Group</creatorcontrib><description>ABSTRACT
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.</description><identifier>ISSN: 1750-2640</identifier><identifier>EISSN: 1750-2659</identifier><identifier>DOI: 10.1111/irv.13292</identifier><identifier>PMID: 38654485</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Aged ; Aged, 80 and over ; cohort design ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - immunology ; Effectiveness ; Electronic Health Records ; Estimates ; Europe - epidemiology ; European Union ; Female ; hospitalisation ; Hospitalization ; Hospitalization - statistics & numerical data ; Humans ; Infections ; Male ; Mortality ; multicountry study ; Older people ; Patient admissions ; Retrospective Studies ; SARS-CoV-2 - immunology ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; Short Communication ; Short Communications ; Vaccination - statistics & numerical data ; vaccine effectiveness ; Vaccine Efficacy ; Vaccines</subject><ispartof>Influenza and other respiratory viruses, 2024-04, Vol.18 (4), p.e13292-n/a</ispartof><rights>2024 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4042-3c1e166d713dffc9533f9bb2829e24933c1aa6251ea7f10e6113b4b044481c9e3</cites><orcidid>0000-0001-7188-8404 ; 0000-0002-9067-090X ; 0000-0002-6396-7265</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040092/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040092/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38654485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Monge, Susana</creatorcontrib><creatorcontrib>Humphreys, James</creatorcontrib><creatorcontrib>Nicolay, Nathalie</creatorcontrib><creatorcontrib>Braeye, Toon</creatorcontrib><creatorcontrib>Van Evercooren, Izaak</creatorcontrib><creatorcontrib>Holm Hansen, Christian</creatorcontrib><creatorcontrib>Emborg, Hanne‐Dorthe</creatorcontrib><creatorcontrib>Sacco, Chiara</creatorcontrib><creatorcontrib>Mateo‐Urdiales, Alberto</creatorcontrib><creatorcontrib>Castilla, Jesús</creatorcontrib><creatorcontrib>Martínez‐Baz, Iván</creatorcontrib><creatorcontrib>Gier, Brechje</creatorcontrib><creatorcontrib>Hahné, Susan</creatorcontrib><creatorcontrib>Meijerink, Hinta</creatorcontrib><creatorcontrib>Kristoffersen, Anja Bråthen</creatorcontrib><creatorcontrib>Machado, Ausenda</creatorcontrib><creatorcontrib>Soares, Patricia</creatorcontrib><creatorcontrib>Nardone, Anthony</creatorcontrib><creatorcontrib>Bacci, Sabrina</creatorcontrib><creatorcontrib>Kissling, Esther</creatorcontrib><creatorcontrib>Nunes, Baltazar</creatorcontrib><creatorcontrib>VEBIS‐EHR Working Group</creatorcontrib><title>Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study</title><title>Influenza and other respiratory viruses</title><addtitle>Influenza Other Respir Viruses</addtitle><description>ABSTRACT
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>cohort design</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Effectiveness</subject><subject>Electronic Health Records</subject><subject>Estimates</subject><subject>Europe - epidemiology</subject><subject>European Union</subject><subject>Female</subject><subject>hospitalisation</subject><subject>Hospitalization</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Infections</subject><subject>Male</subject><subject>Mortality</subject><subject>multicountry study</subject><subject>Older people</subject><subject>Patient admissions</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Communication</subject><subject>Short Communications</subject><subject>Vaccination - statistics & numerical data</subject><subject>vaccine effectiveness</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><issn>1750-2640</issn><issn>1750-2659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kctu1DAUhiMEohdY8ALIEhsqMTO-JZOwQXMJdKTSQS0dsbMc56S4TexiJ6lmxyPwFrwXT4KnU0YFCW_Okc7n_1z-KHpB8JCEN9KuHxJGM_oo2ifjGA9oEmePdznHe9GB91cYx0ka86fRHkuTmPM03o9-5lUFqtU9GPAe2Qp9mU6HZBijj9bYXtZgWjRbrhbzX99_kAytpFI6oGjeOW0ukUSfwGlbPvw5t4020ihA2qD8YpTnEzSznWmdBv8GLVVrC3CotejU9tBscoope4smaJVPF-ehU358hk6hvbXuGp23Xbl-Fj2pZO3h-X08jC7e559nx4OT5YfFbHIyUBxzOmCKAEmSckxYWVUqixmrsqKgKc2A8oyFupQJjQnIcUUwJISwgheYh2sQlQE7jN5tdW-6ooFShfWdrMWN0410a2GlFn9XjP4qLm0vCMEc44wGhdf3Cs5-68C3otFeQV1LA7bzgmGexISleIO--ge9sp0zYb87CpMsZSRQR1tKOeu9g2o3DcFi478I_os7_wP78uH4O_KP4QEYbYFbXcP6_0picbbaSv4Gmbu3zg</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Monge, Susana</creator><creator>Humphreys, James</creator><creator>Nicolay, Nathalie</creator><creator>Braeye, Toon</creator><creator>Van Evercooren, Izaak</creator><creator>Holm Hansen, Christian</creator><creator>Emborg, Hanne‐Dorthe</creator><creator>Sacco, Chiara</creator><creator>Mateo‐Urdiales, Alberto</creator><creator>Castilla, Jesús</creator><creator>Martínez‐Baz, Iván</creator><creator>Gier, Brechje</creator><creator>Hahné, Susan</creator><creator>Meijerink, Hinta</creator><creator>Kristoffersen, Anja Bråthen</creator><creator>Machado, Ausenda</creator><creator>Soares, Patricia</creator><creator>Nardone, Anthony</creator><creator>Bacci, Sabrina</creator><creator>Kissling, Esther</creator><creator>Nunes, Baltazar</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7188-8404</orcidid><orcidid>https://orcid.org/0000-0002-9067-090X</orcidid><orcidid>https://orcid.org/0000-0002-6396-7265</orcidid></search><sort><creationdate>202404</creationdate><title>Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study</title><author>Monge, Susana ; Humphreys, James ; Nicolay, Nathalie ; Braeye, Toon ; Van Evercooren, Izaak ; Holm Hansen, Christian ; Emborg, Hanne‐Dorthe ; Sacco, Chiara ; Mateo‐Urdiales, Alberto ; Castilla, Jesús ; Martínez‐Baz, Iván ; Gier, Brechje ; Hahné, Susan ; Meijerink, Hinta ; Kristoffersen, Anja Bråthen ; Machado, Ausenda ; Soares, Patricia ; Nardone, Anthony ; Bacci, Sabrina ; Kissling, Esther ; Nunes, Baltazar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4042-3c1e166d713dffc9533f9bb2829e24933c1aa6251ea7f10e6113b4b044481c9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>cohort design</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Effectiveness</topic><topic>Electronic Health Records</topic><topic>Estimates</topic><topic>Europe - epidemiology</topic><topic>European Union</topic><topic>Female</topic><topic>hospitalisation</topic><topic>Hospitalization</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Infections</topic><topic>Male</topic><topic>Mortality</topic><topic>multicountry study</topic><topic>Older people</topic><topic>Patient admissions</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Communication</topic><topic>Short Communications</topic><topic>Vaccination - statistics & numerical data</topic><topic>vaccine effectiveness</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Monge, Susana</creatorcontrib><creatorcontrib>Humphreys, James</creatorcontrib><creatorcontrib>Nicolay, Nathalie</creatorcontrib><creatorcontrib>Braeye, Toon</creatorcontrib><creatorcontrib>Van Evercooren, Izaak</creatorcontrib><creatorcontrib>Holm Hansen, Christian</creatorcontrib><creatorcontrib>Emborg, Hanne‐Dorthe</creatorcontrib><creatorcontrib>Sacco, Chiara</creatorcontrib><creatorcontrib>Mateo‐Urdiales, Alberto</creatorcontrib><creatorcontrib>Castilla, Jesús</creatorcontrib><creatorcontrib>Martínez‐Baz, Iván</creatorcontrib><creatorcontrib>Gier, Brechje</creatorcontrib><creatorcontrib>Hahné, Susan</creatorcontrib><creatorcontrib>Meijerink, Hinta</creatorcontrib><creatorcontrib>Kristoffersen, Anja Bråthen</creatorcontrib><creatorcontrib>Machado, Ausenda</creatorcontrib><creatorcontrib>Soares, Patricia</creatorcontrib><creatorcontrib>Nardone, Anthony</creatorcontrib><creatorcontrib>Bacci, Sabrina</creatorcontrib><creatorcontrib>Kissling, Esther</creatorcontrib><creatorcontrib>Nunes, Baltazar</creatorcontrib><creatorcontrib>VEBIS‐EHR Working Group</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Influenza and other respiratory viruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Monge, Susana</au><au>Humphreys, James</au><au>Nicolay, Nathalie</au><au>Braeye, Toon</au><au>Van Evercooren, Izaak</au><au>Holm Hansen, Christian</au><au>Emborg, Hanne‐Dorthe</au><au>Sacco, Chiara</au><au>Mateo‐Urdiales, Alberto</au><au>Castilla, Jesús</au><au>Martínez‐Baz, Iván</au><au>Gier, Brechje</au><au>Hahné, Susan</au><au>Meijerink, Hinta</au><au>Kristoffersen, Anja Bråthen</au><au>Machado, Ausenda</au><au>Soares, Patricia</au><au>Nardone, Anthony</au><au>Bacci, Sabrina</au><au>Kissling, Esther</au><au>Nunes, Baltazar</au><aucorp>VEBIS‐EHR Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study</atitle><jtitle>Influenza and other respiratory viruses</jtitle><addtitle>Influenza Other Respir Viruses</addtitle><date>2024-04</date><risdate>2024</risdate><volume>18</volume><issue>4</issue><spage>e13292</spage><epage>n/a</epage><pages>e13292-n/a</pages><issn>1750-2640</issn><eissn>1750-2659</eissn><abstract>ABSTRACT
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>38654485</pmid><doi>10.1111/irv.13292</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7188-8404</orcidid><orcidid>https://orcid.org/0000-0002-9067-090X</orcidid><orcidid>https://orcid.org/0000-0002-6396-7265</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-2640 |
| ispartof | Influenza and other respiratory viruses, 2024-04, Vol.18 (4), p.e13292-n/a |
| issn | 1750-2640 1750-2659 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11040092 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Aged Aged, 80 and over cohort design COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Effectiveness Electronic Health Records Estimates Europe - epidemiology European Union Female hospitalisation Hospitalization Hospitalization - statistics & numerical data Humans Infections Male Mortality multicountry study Older people Patient admissions Retrospective Studies SARS-CoV-2 - immunology SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 Short Communication Short Communications Vaccination - statistics & numerical data vaccine effectiveness Vaccine Efficacy Vaccines |
| title | Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A55%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20XBB.1.5%20Monovalent%20COVID%E2%80%9019%20Vaccines%20During%20a%20Period%20of%20XBB.1.5%20Dominance%20in%20EU/EEA%20Countries,%20October%20to%20November%202023:%20A%20VEBIS%E2%80%90EHR%20Network%20Study&rft.jtitle=Influenza%20and%20other%20respiratory%20viruses&rft.au=Monge,%20Susana&rft.aucorp=VEBIS%E2%80%90EHR%20Working%20Group&rft.date=2024-04&rft.volume=18&rft.issue=4&rft.spage=e13292&rft.epage=n/a&rft.pages=e13292-n/a&rft.issn=1750-2640&rft.eissn=1750-2659&rft_id=info:doi/10.1111/irv.13292&rft_dat=%3Cproquest_pubme%3E3046019831%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3046019831&rft_id=info:pmid/38654485&rfr_iscdi=true |